Marion Jung joined Earlybird in 1999 as an Associate and was promoted to Principal in 2002. Marion focuses on innovative technologies deployed in the medical device and pharmaceutical industries.

Since joining Earlybird, Marion has been involved in building Earlybird´s portfolio in the healthcare markets in Europe and the US. With her broad international network, Marion works closely with Earlybird´s portfolio companies to help them achieve their value-creating milestones as well as being involved from Earlybird's initial investment through subsequent financing rounds. These companies include Amaxa AG (Cologne) and Dianoema S.p.A., which listed on the Borsa Italiana (Milan: NOE.MI). Marion´s most recent investment is Sidec Technologies AB (Stockholm).

Marion joined Earlybird after her postdoctoral training in molecular biology at the Ludwig-Maximilians-University in Munich. She earned her PhD under the supervision of Prof. Dr. Svante Pääbo while working on genetic peculiarities of mammalian mitochondria. She gained further research expertise in programs at Arizona State University in Phoenix, Arizona and at the Marine Biological Laboratory in Woods Hole, Massachusetts.

Marion received a Dipl.- Biol. (MS equivalent) from the Ludwig-Maximilians-University in Munich. She is the author of several articles that have been published in peer reviewed journals including Molecular Biology of the Cell, Nucleic Acid Research and Annals of Neurology.